Supported by a £10 million award from Wellcome, RESPECT-TB brings together 15 research organisations, public health bodies and national TB programmes across India, Kazakhstan, Mozambique, South Africa and Vietnam. The programme will generate evidence to improve patient care, strengthen research capacity and inform national and global TB policy.
Tuberculosis remains the world's leading infectious disease killer, causing an estimated 1.23 million deaths each year. While new six-month, bedaquiline-based regimens have transformed treatment for drug-resistant TB, increasing cure rates to around 90%, resistance to these medicines is beginning to emerge, threatening one of the biggest advances in TB care in decades.
RESPECT-TB will investigate the population level prevalence of resistance to the new drugs used to treat drug-resistant TB, as well as asking why and how this resistance develops by combining genomic sequencing, laboratory science and detailed clinical data.
See the full story on the Nuffield Department of Medicine website.